<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Arq. Bras. Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26761372</article-id>
      <article-id pub-id-type="pmc">4693669</article-id>
      <article-id pub-id-type="doi">10.5935/abc.20150052</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Resolution of Extensive Coronary Thrombosis under Rivaroxaban
Treatment</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Yuksel</surname>
            <given-names>Murat</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yildiz</surname>
            <given-names>Abdulkadir</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tapan</surname>
            <given-names>Umit</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ertas</surname>
            <given-names>Faruk</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alan</surname>
            <given-names>Sait</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label>Dicle University, School of Medicine, Cardiology
Department, Diyarbakir - Turkey</aff>
      <aff id="aff02"><label>2</label>Boston University Medical Center, Hematology/Oncology
Department, Boston - USA</aff>
      <author-notes>
        <corresp id="c01"><bold>Mailing Address: Murat Yuksel,</bold> Dicle Universitesi Kalp
Hastanesi 1.kat Kardiyoloji Anabilimdali, Sur. Postal Code 21280, Diyarbakir -
Turkey. E-mail: <email>myuksel44@yandex.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>12</month>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <month>12</month>
        <year>2015</year>
      </pub-date>
      <volume>105</volume>
      <issue>6</issue>
      <fpage>642</fpage>
      <lpage>646</lpage>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly
cited.</license-p>
        </license>
      </permissions>
      <kwd-group>
        <kwd>Coronary Thrombosis / therapy</kwd>
        <kwd>Anticoagulants</kwd>
        <kwd>Blood Coagulation / genetics</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Genetic mutations resulting in a hypercoagulable state are well-defined risk factors for
venous thrombosis. However, there are few cases of arterial thrombosis, including
coronary thrombosis, in patients with such genetic mutations described in the
literature.</p>
    </sec>
    <sec>
      <title>Case Report</title>
      <p>A 26-year-old male admitted to the emergency department with a new-onset chest pain for
two days. His physical examination was unremarkable. Electrocardiogram (ECG) showed
biphasic T wave changes in leads V<sub>2-4</sub>(<xref ref-type="fig" rid="f01">Figure
1</xref>). The patient had a history of warfarin use for 6 months due to a deep vein
thrombosis (DVT) suffered 2 years before. Bedside echocardiogram revealed slight
hypokinesis of anterior wall with an ejection fraction of 52%. In laboratory analysis,
creatinine kinase-MB and troponin-I levels were slightly elevated (32 ng/ml and 0.44
ng/ml, respectively). The patient was transferred to the coronary care unit with the
diagnosis of non-ST segment elevation myocardial infarction. Coronary angiogram revealed
multiple segmentary thrombotic foci along the left anterior descending (LAD) artery with
Thrombolysis In Myocardial Infarction (TIMI)-III flow and normal circumflex and right
coronary arteries (<xref ref-type="fig" rid="f02">Figure 2A</xref>, <xref ref-type="fig" rid="f03">Video 1</xref>). Manual thrombus aspiration or thrombectomy device were not
considered because of the widespread nature of thrombosis throughout LAD. Initially,
intracoronary tirofiban at a 10-&#xB5;g/kg dose was given in 3 minutes, followed by
0.15 &#xB5;g/kg/min intravenous infusion for 24 hours in addition to subcutaneous
enoxaparin. Control angiogram revealed slight improvement (<xref ref-type="fig" rid="f02">Figure 2B</xref>, <xref ref-type="fig" rid="f04">Video 2</xref>). Then the
patient was started on rivaroxaban 20 mg daily, for 8 weeks and control angiogram
revealed complete resolution of the thrombus (<xref ref-type="fig" rid="f02">Figure
2C</xref>, <xref ref-type="fig" rid="f05">Videos 3</xref> and <xref ref-type="fig" rid="f06">4</xref>). Meanwhile, thrombophilia work up resulted in prothrombin gene
mutation (homozygous, G20210A) and homozygous mutation in plasminogen activator
inhibitor type 1 (PAI-1) gene [4G/4G]. The patient also had a lupus anticoagulant at the
time of initial presentation but did not have anti-cardiolipin antibodies or anti-beta2
glycoprotein-I antibodies. Also, his lupus anticoagulant was negative.</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Electrocardiogram on admission showing biphasic T wave changes in leads
V<sup><xref rid="r02" ref-type="bibr">2</xref>-<xref rid="r04" ref-type="bibr">4</xref></sup>.</p>
        </caption>
        <graphic xlink:href="abc-105-06-0642-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Antero-posterior cranial view showing left anterior descending artery
<bold>A</bold>. At presentation with widespread thrombotic foci,
<bold>B</bold>. After tirofiban infusion with a slight regression of thrombotic
foci and C. Complete resolution of thrombotic foci after use of rivaroxaban for 8
weeks.</p>
        </caption>
        <graphic xlink:href="abc-105-06-0642-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>Video 1</label>
        <caption>
          <p>Coronary angiogram showing the filling defects throughout the left anterior
descending artery on antero-posterior cranial projection at presentation.</p>
        </caption>
        <media xlink:href="abc-105-06-0642-m01.mp4" mimetype="video" mime-subtype="mp4" orientation="portrait" id="d36e184" position="anchor"/>
      </fig>
      <fig id="f04" orientation="portrait" position="float">
        <label>Video 2</label>
        <caption>
          <p>A slight regressions of thrombotic foci is seen on antero-posterior cranial
projection of angiogram after tirofiban infusion.</p>
        </caption>
        <media xlink:href="abc-105-06-0642-m02.mp4" mimetype="video" mime-subtype="mp4" orientation="portrait" id="d36e191" position="anchor"/>
      </fig>
      <fig id="f05" orientation="portrait" position="float">
        <label>Video 3</label>
        <caption>
          <p>Coronary angiograms demonstrating resolution of extensive thrombotic foci in left
anterior descending artery on antero-posterior cranial projection after use of
rivaroxaban for 8 weeks.</p>
        </caption>
        <media xlink:href="abc-105-06-0642-m03.mp4" mimetype="video" mime-subtype="mp4" orientation="portrait" id="d36e198" position="anchor"/>
      </fig>
      <fig id="f06" orientation="portrait" position="float">
        <label>Video 4</label>
        <caption>
          <p>Coronary angiograms demonstrating resolution of extensive thrombotic foci in left
anterior descending artery on right cranial projection after use of rivaroxaban
for 8 weeks.</p>
        </caption>
        <media xlink:href="abc-105-06-0642-m04.mp4" mimetype="video" mime-subtype="mp4" orientation="portrait" id="d36e205" position="anchor"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>The key clinical feature in this case is identifying the cause of the extensive coronary
thrombosis in such a young man. We concentrated on thrombophilia because the patient had
a history of DVT without any predisposing cause.</p>
      <p>The plasminogen activator inhibitor-1 (PAI-1) level is crucial in the regulation of
plasminogen activity and high levels of PAI-1 are associated with a pro-thrombotic
state. A common guanosine insertion/deletion gene polymorphism of 4G/5G located at the
675<sup>th</sup> base pair upstream of the start point of translation regulates PAI-1
levels. Homozygosity for the deletion genotype (4G/4G) has been shown to cause higher
levels of PAI-1 compared to 4G/5G genotype<sup><xref rid="r01" ref-type="bibr">1</xref></sup>. The clinical significance of homozygous PAI-1 mutation by itself is
not clear, but there are reports suggesting increased frequency of thrombotic events
when found together with other pro-thrombotic situations<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r03" ref-type="bibr">3</xref></sup>. The association
between prothrombin gene mutation and thrombosis is well established; this mutation
confers a 2.8 fold increase in the thrombotic risk.<sup><xref rid="r04" ref-type="bibr">4</xref></sup> Our patient had a history of DVT 2 years prior to this
presentation, suggesting his tendency to develop thrombosis. After obtaining the results
of hypercoagulable work up, we felt imperative to treat him with an anticoagulant
acutely as well as for lifelong. Rivaroxaban, a direct factor-Xa inhibitor approved for
venous thromboembolism treatment/prevention, was chosen because of its easy
administration compared to the subcutaneous and intravenous forms of heparin products
and quick action and fewer drug interactions compared to warfarin.</p>
      <p>This case stands as the first report of a patient presenting with acute coronary
syndrome caused by widespread non-occlusive thrombotic foci in coronary artery due to
prothrombin gene mutation and/or PAI-1 mutation. Additive effects of hypercoagulable
states are well known and this case reiterates that fact with an unprovoked venous
thrombosis and a widespread arterial thrombotic episode in a young patient showing no
other known risk factors for arterial or venous thrombosis. It also highlights the
importance of hypercoagulable work up in such patients.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusion</title>
      <p>We demonstrated successful resolution of the widespread coronary thrombosis with
rivaroxaban 20 mg daily, which was important to confirm the non-atherosclerotic nature
of the occlusion.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="con">
        <p>
<bold>Author contributions</bold>
</p>
        <p>Conception and design of the research:Yuksel M, Yildiz A. Acquisition of data: Yuksel M,
Yildiz A, Ertas F. Analysis and interpretation of the data: Yuksel M, Tapan U, Ertas F.
Writing of the manuscript: Yuksel M, Yildiz A, Tapan U. Critical revision of the
manuscript for intellectual content: Yildiz A, Tapan U, Ertas F, Alan S. Supervision /
as the major investigador:Yuksel M, Tapan U, Alan S.</p>
      </fn>
      <fn fn-type="conflict">
        <p>
<bold>Potential Conflict of Interest</bold>
</p>
        <p>No potential conflict of interest relevant to this article was reported.</p>
      </fn>
      <fn fn-type="supported-by">
        <p>
<bold>Sources of Funding</bold>
</p>
        <p>There were no external funding sources for this study.</p>
      </fn>
      <fn fn-type="other">
        <p>
<bold>Study Association</bold>
</p>
        <p>This study is not associated with any thesis or dissertation work.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khosravi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Zarei</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ahmadvand</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Akbarzadeh-Pasha</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Savadi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Zarnani</surname>
              <given-names>AH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Association between plasminogen activator inhibitor 1 gene mutation
and different subgroups of recurrent miscarriage and implantation
failure</article-title>
          <source>J Assist Reprod Genet</source>
          <year>2014</year>
          <volume>31</volume>
          <issue>1</issue>
          <fpage>121</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="pmid">24189965</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Segu&#xED;</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Estell&#xE9;s</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mira</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Espa&#xF1;a</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Villa</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Falc&#xF3;</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>PAI-1 promoter 4G/5G genotype as an additional risk factor for venous
thrombosis in subjects with genetic thrombophilic defects</article-title>
          <source>Br J Haematol</source>
          <year>2000</year>
          <volume>111</volume>
          <issue>1</issue>
          <fpage>122</fpage>
          <lpage>128</lpage>
          <pub-id pub-id-type="pmid">11091191</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bolan</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Krishnamurti</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Carrington</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Alving</surname>
              <given-names>BM</given-names>
            </name>
          </person-group>
          <article-title>Association of protein S deficiency with thrombosis in a kindred with
increased levels of plasminogen activator inhibitor-1</article-title>
          <source>Ann Intern Med</source>
          <year>1993</year>
          <volume>119</volume>
          <issue>8</issue>
          <fpage>779</fpage>
          <lpage>785</lpage>
          <pub-id pub-id-type="pmid">8379599</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Poort</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Rosendaal</surname>
              <given-names>FR</given-names>
            </name>
            <name>
              <surname>Reitsma</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Bertina</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>A common genetic variation in the 3'-untranslated region of the
prothrombin gene is associated with elevated plasma prothrombin levels and an
increase in venous thrombosis</article-title>
          <source>Blood</source>
          <year>1996</year>
          <volume>88</volume>
          <issue>10</issue>
          <fpage>3698</fpage>
          <lpage>3703</lpage>
          <pub-id pub-id-type="pmid">8916933</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
